Today saw a rare convergence of two targets.
I've been waiting for SBTX:SkinBioTherapeutics to hit 20p bid price in order to sell my SIPP holding. After missing out on 19.75p on Friday I thought my chance had gone, but this morning it came back and the limit sell order triggered, selling for 20.11p making a profit of £496.16 (49%) and liberating £1,496.10.
At exactly the same time, VRS:Versarien dipped bellow 100p, which has always been my target to buy back in. I really thought I had missed the chance, as resistance seemed to be at around 124p and it never got near my target. As soon as it went below 100p I bought some, convinced it was about to head north again as others like myself spotted a good deal.
I bought 1,505 shares at 98.85p costing £1,499.64. There was much celebrating, until close of business when the price had plummeted to a purchase price of 86p. So I managed a 15% loss of £232 on day one!
Never mind eh.
I'm just really happy to be back in VRS:Versarien as I didn't really want to sell. With hindsight I'm glad I did, as I made £4,000 profit in a very short period of time. There's a hell of a lot going on with them, and they have so many divisions developing the next most important tech that we're likely to see. They are doing it with global players, which takes time. They may decline further, which will be annoying, but from reading the bulletin boards it's clear there is active shorting and a concerted attack on the share price. That won't last.
I waited 3 years for OPTI:Optibiotix to become profitable for me. I'm very happy to wait as long for VRS:Versarien, and if they can stay this low for another month I'll have £2,000 from my pension transfer to add some more.
Meanwhile the portfolio is up by £1,544 on the week so far, despite cashing in £500 paper profit from the sale today, with OPTI:Optibiotix and CEY:Centamin being the main risers.
I really can't express just how happy I am to be back in VRS:Versarien, especially coming just a week after getting back into CWR:Ceres Power, another of my favourites. I've been watching for a long time yearning to be able to call myself a shareholder in both.
Tuesday, 19 February 2019
Sunday, 17 February 2019
Week 184 Review - Big week for bad news
I wrote a short blog on Thursday detailing the misery of "Bad news day", and that day single-handedly dragged the whole portfolio down this week. It was heading for a modest gain, but ended up with a £1,263 reduction in value, with the buffer between value and cost only £765 and total value down to £98,327.
It will come as no surprise that the worst performer this week was MTFB:Motif Bio. The FDA rejection caused a 27% potential profit to drop 96% of the amount I payed for the shares end up at a 69% loss. That's paper loss of £1,745 from what was around £600 paper profit on Wednesday. There is one tiny glimmer of light in this disaster. I've been watching CWR:Ceres Power for ages, and vowed to buy back in if the price went below 150p which it did on Monday. In order to buy some, I sold 25% of my MTFB:Motif Bio holding. That was 2,530 shares sold at 42.7725p making profit of £263.08 (32.1%). I used the proceeds to buy 733 shares of CWR:Ceres Power at 145.9p costing £1,081.40. They slipped a bit lower and so are 7% down including commission, but I'm still happy I bought when I did and glad to be back in.
KIBO:Kibo Energy waited until later in the day to deliver the bombshell that TANESCO have suddenly decided KIBO:Kibo Energy don't qualify to apply for a Power Purchase Agreement. This follows years (literally) of discussion and "close cooperation". The share price pretty much halved, but as it has already dropped so far, the drop against my original purchase price was 12%. These are now down by 89% and losing £2,343. I have a horrible feeling this is going to go south and I'll end up with a big loss which will have a dire effect on my performance stats.
N4P:N4 Pharma was another big loser, falling 7% possibly in sympathy to MTFB:Motif Bio. I may give up investing in junior pharma companies. It seems to me everything is stacked against them.
There was some nice price action this week. OPTI:Optibiotix yo-yoed quite a bit but ended up 1p ahead. It's only a tiny percentage but worth £800.
CEY:Centamin gave a very upbeat statement about gold reserves at their Ivory Coast property, which helped the price climb by 6%. That leaves my ISA holding only 5% (£81) down, and my SIPP holding 17% (£343) up, so looking good and some nice dividends not too far away.
SBTX:SkinBioTherapeutics had a great week, climbing 7% of my purchase price in the ISA and 12% in the SIPP. That leaves the ISA holding down 9% (£162) and the SIPP holding up 38% (£375). On Friday morning I almost sold them at 19.75p which would have made £469 (47%) profit, but it was below my target of 20p so I didn't accept the offer. I really wish I had, as it dropped to 18.5p by the end of the day. I wanted the cash to buy VRS:Versarien, which is dropping to my target price of under 100p. I need to be ready with the cash if it happens, as I don't think it will stay there for long. Shame it didn't drop earlier in the week else I may have sacrificed some more MTFB:Motif Bio shares, which would have been a great move!
CAML:Central Asia Metals had a great week, climbing 9% and going to paper profit of £2,111 (39%). This year's dividend is going to be massive - I'm very excited!
Share of the Week is once again IKA:Ilika, which has at last shown some signs it may be able to sell its tech. The price climbed an impressive 20 and is now only 21% down on my purchase price. I think this was one of my worst timed purchases, but patience may yet be rewarded, unlike with most of my disasters which all seem to be getting worse.
Ouch - that's no gap at all!
Well below the trendline. It's not good.
The ISA and share accounts look like this
Portfolio cost went up as a result of re-investing profits from MTFB:Motif Bio in CWR:Ceres Power and cash went down £11 as I wanted as many shares as I could buy so included some of the ISA cash. Portfolio value savaged by £2,307 as a result of MTFB:Motif Bio and KIBO:Kibo Energy crashing, but potential profits hardly affected, as OPTI:Optibiotix increased a little, so just the remaining MTFB:Motif Bio profits were lost. The sale increased the average performance for year 4 by £35 a month, but had a tiny effect on long term performance, improving it by just £3 a month. The percentage would have dropped from 10.3% to 10.2% this week, but the sale kept it at 10.3%.
I forgot to add the increase in cost to the chart, but it will be there next week. Too busy being depressed about the drop in value to notice that.
Into the red and well below the trendline.
The SIPP looks like this after week 168
Excellent week with nearly all shares increasing in value and a very different picture to the ISA.
Still a nice gap here, but there needs to be to offset the ISA woes.
Back on the trendline, so I'm happy
The trading account looks like this after week 134
A rare sight to see positive potential profits in this account! CAML:Central Asia Metals is on a roll, and hopefully can keep climbing to my target of 300p when I may consider selling and getting this portfolio into profit. Everything else in this account is desperate, so all my hopes are pinned on CAML:Central Asia Metals keeping up the good work.
That's what I call a sustained rise!
We're above the trendline, which is about as positive as I can get about this chart.
That's it for another week. A week of much turmoil. I'm very concerned with the behaviour of the FDA towards MTFB:Motif Bio. They had plenty of opportunity to mention they wanted more information on potential liver toxicity, so why wait until after the submission? All this does is cripple the MTFB:Motif Bio share price and makes them a perfect target for an aggressive buy-out - hmm - by an American pharma company maybe? Nah - that's me being cynical - must behave!
As for TANESCO - I really haven't a clue what's going on there, but I'm tempted to be a hell of a lot more cynical. Years of effort has been pretty much wasted. If they never had any intention of granting a PPA then they should have said so from the outset. It's cost millions to get this far, and much of that is debt hanging around KIBO:Kibo Energy's neck, so I'm really concerned about the viability of the company without this agreement.
I hope we don't get another day like Thursday for a long, long time...
It will come as no surprise that the worst performer this week was MTFB:Motif Bio. The FDA rejection caused a 27% potential profit to drop 96% of the amount I payed for the shares end up at a 69% loss. That's paper loss of £1,745 from what was around £600 paper profit on Wednesday. There is one tiny glimmer of light in this disaster. I've been watching CWR:Ceres Power for ages, and vowed to buy back in if the price went below 150p which it did on Monday. In order to buy some, I sold 25% of my MTFB:Motif Bio holding. That was 2,530 shares sold at 42.7725p making profit of £263.08 (32.1%). I used the proceeds to buy 733 shares of CWR:Ceres Power at 145.9p costing £1,081.40. They slipped a bit lower and so are 7% down including commission, but I'm still happy I bought when I did and glad to be back in.
KIBO:Kibo Energy waited until later in the day to deliver the bombshell that TANESCO have suddenly decided KIBO:Kibo Energy don't qualify to apply for a Power Purchase Agreement. This follows years (literally) of discussion and "close cooperation". The share price pretty much halved, but as it has already dropped so far, the drop against my original purchase price was 12%. These are now down by 89% and losing £2,343. I have a horrible feeling this is going to go south and I'll end up with a big loss which will have a dire effect on my performance stats.
N4P:N4 Pharma was another big loser, falling 7% possibly in sympathy to MTFB:Motif Bio. I may give up investing in junior pharma companies. It seems to me everything is stacked against them.
There was some nice price action this week. OPTI:Optibiotix yo-yoed quite a bit but ended up 1p ahead. It's only a tiny percentage but worth £800.
CEY:Centamin gave a very upbeat statement about gold reserves at their Ivory Coast property, which helped the price climb by 6%. That leaves my ISA holding only 5% (£81) down, and my SIPP holding 17% (£343) up, so looking good and some nice dividends not too far away.
SBTX:SkinBioTherapeutics had a great week, climbing 7% of my purchase price in the ISA and 12% in the SIPP. That leaves the ISA holding down 9% (£162) and the SIPP holding up 38% (£375). On Friday morning I almost sold them at 19.75p which would have made £469 (47%) profit, but it was below my target of 20p so I didn't accept the offer. I really wish I had, as it dropped to 18.5p by the end of the day. I wanted the cash to buy VRS:Versarien, which is dropping to my target price of under 100p. I need to be ready with the cash if it happens, as I don't think it will stay there for long. Shame it didn't drop earlier in the week else I may have sacrificed some more MTFB:Motif Bio shares, which would have been a great move!
CAML:Central Asia Metals had a great week, climbing 9% and going to paper profit of £2,111 (39%). This year's dividend is going to be massive - I'm very excited!
Share of the Week is once again IKA:Ilika, which has at last shown some signs it may be able to sell its tech. The price climbed an impressive 20 and is now only 21% down on my purchase price. I think this was one of my worst timed purchases, but patience may yet be rewarded, unlike with most of my disasters which all seem to be getting worse.
Ouch - that's no gap at all!
Well below the trendline. It's not good.
The ISA and share accounts look like this
| Weekly Change | |||
| Cash | £28.03 | -£11.21 | |
| Portfolio cost | £57,246.22 | +£274.28 | |
| Portfolio sell value (bid price - commission) | £54,808.06 | (-4.3%) | -£2,307.79 |
| Potential profits | £8,331.17 | -£389.08 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £1,077.60 | +£263.07 | |
| Yr 4 Average monthly cash profit | £172.65 | (3.6%) | +£35.82 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,774.72 | +£263.07 | |
| Average monthly cash profit | £492.32 | (10.3%) | +£3.54 |
| (Sold stocks profit + Dividends - Fees / Months) |
Portfolio cost went up as a result of re-investing profits from MTFB:Motif Bio in CWR:Ceres Power and cash went down £11 as I wanted as many shares as I could buy so included some of the ISA cash. Portfolio value savaged by £2,307 as a result of MTFB:Motif Bio and KIBO:Kibo Energy crashing, but potential profits hardly affected, as OPTI:Optibiotix increased a little, so just the remaining MTFB:Motif Bio profits were lost. The sale increased the average performance for year 4 by £35 a month, but had a tiny effect on long term performance, improving it by just £3 a month. The percentage would have dropped from 10.3% to 10.2% this week, but the sale kept it at 10.3%.
I forgot to add the increase in cost to the chart, but it will be there next week. Too busy being depressed about the drop in value to notice that.
Into the red and well below the trendline.
The SIPP looks like this after week 168
| Weekly Change | |||
| Cash | £122.76 | +£0 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,845.62 | (10.6%) | +£1,031.23 |
| Potential profits | £7,920.30 | +£1,022.71 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£11.28 | (-0.4%) | +£1.02 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £298.53 | (9.5%) | -£1.79 |
| (Sold stocks profit + Dividends - Fees / Months) |
Excellent week with nearly all shares increasing in value and a very different picture to the ISA.
Still a nice gap here, but there needs to be to offset the ISA woes.
Back on the trendline, so I'm happy
The trading account looks like this after week 134
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,504.07 | (-35.2%) | +£13.42 |
| Potential profits | £12.99 | +£12.99 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £28.08 | (14.5%) | -£0.97 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.48 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
A rare sight to see positive potential profits in this account! CAML:Central Asia Metals is on a roll, and hopefully can keep climbing to my target of 300p when I may consider selling and getting this portfolio into profit. Everything else in this account is desperate, so all my hopes are pinned on CAML:Central Asia Metals keeping up the good work.
That's what I call a sustained rise!
We're above the trendline, which is about as positive as I can get about this chart.
That's it for another week. A week of much turmoil. I'm very concerned with the behaviour of the FDA towards MTFB:Motif Bio. They had plenty of opportunity to mention they wanted more information on potential liver toxicity, so why wait until after the submission? All this does is cripple the MTFB:Motif Bio share price and makes them a perfect target for an aggressive buy-out - hmm - by an American pharma company maybe? Nah - that's me being cynical - must behave!
As for TANESCO - I really haven't a clue what's going on there, but I'm tempted to be a hell of a lot more cynical. Years of effort has been pretty much wasted. If they never had any intention of granting a PPA then they should have said so from the outset. It's cost millions to get this far, and much of that is debt hanging around KIBO:Kibo Energy's neck, so I'm really concerned about the viability of the company without this agreement.
I hope we don't get another day like Thursday for a long, long time...
Thursday, 14 February 2019
Worst news day ever
What a disastrous day for news!
MTFB:Motif Bio had its new drug application for Iclaprim turned down by the FDA because they require the application to "further evaluate the risk for liver toxicity".
The share price crashed 73% and my holding with around £500 paper profit now has paper loss of £1,704.
Aaaaarrrrghhhh!!!!!!
The only ray of sunshine is that I sold 25% of my holding on Monday to buy some CWR:Ceres Power shares.
I was sulking all day about that, but came home to an RNS from KIBO:Kibo Energy to say that TANESCO have rejected their Power Purchase Agreement application, saying Kibo "did not qualify to compete in the next stage of the bidding process" but giving absolutely no reason.
KIBO:Kibo Energy shares crashed 50% as a result, so my holding is now down 89% with paper loss of £2,343.
Meanwhile OPT:Optibiotix slipped another 3p which cost me £2,400
Absolutely bloody horrible
The combined portfolios hover on the very cusp, being just £27 in the black
The week had been so wonderful up to today - now it's all gone to hell in a handcart.
I'm no longer looking forward to writing tomorrow's review and I'm off to the pub to drown my sorrows!
MTFB:Motif Bio had its new drug application for Iclaprim turned down by the FDA because they require the application to "further evaluate the risk for liver toxicity".
The share price crashed 73% and my holding with around £500 paper profit now has paper loss of £1,704.
Aaaaarrrrghhhh!!!!!!
The only ray of sunshine is that I sold 25% of my holding on Monday to buy some CWR:Ceres Power shares.
I was sulking all day about that, but came home to an RNS from KIBO:Kibo Energy to say that TANESCO have rejected their Power Purchase Agreement application, saying Kibo "did not qualify to compete in the next stage of the bidding process" but giving absolutely no reason.
KIBO:Kibo Energy shares crashed 50% as a result, so my holding is now down 89% with paper loss of £2,343.
Meanwhile OPT:Optibiotix slipped another 3p which cost me £2,400
Absolutely bloody horrible
The combined portfolios hover on the very cusp, being just £27 in the black
The week had been so wonderful up to today - now it's all gone to hell in a handcart.
I'm no longer looking forward to writing tomorrow's review and I'm off to the pub to drown my sorrows!
Saturday, 9 February 2019
Week 183 Review - Promising start obliterated over last two days
The week was going pretty well aside from a slight slip in OPTI:Optibiotix, but CAML:Central Asia Metals was going great, and even the trading account holding went into profit. However the last 2 days were a disaster, with OPTI:Optibiotix slipping further and most of the gains made early in the week wiped out. Portfolio value dropped by £3,162 so the buffer between value and cost is down to £2,028 and overall portfolio value dips back below £100K at £99,327. All rather upsetting.
Worst performer was N4P:N4 Pharma which has seen a mini rally over the last few weeks, but a placing announced today caused the price to plummet down to the placing price, so it's down 15% and losing 56%.
RED:RedT Energy dropped another 8% for no apparent reason, and is sliding relentlessly as holders continue to doubt they can turn a profit, despite having a great product. These are 59% down after looking like things might be improving a few weeks ago.
MMX:Minds + Machines is being played by traders if the recent invasion of the bulletin board by trolls is anything to go on. I still believe this is a very cash generative company - they just need to prove it and dish some out as a dividend. Another 7% drop this week sees it losing 36% now.
IQE:IQE is also under continued shorting pressure, and lacklustre results from the chip manufacturers has hit them badly this week, dropping 6% in my SIPP and 8% in my trading account.
OPTI:Optibiotix dropped 4p (6%) the same as last week, despite more good news. I fear these are set to drift until either news of revenues or one of the anticipated big deals. I still have paper profits of £12,000 which are the only things keeping my portfolios in the black.
There was some good news this week. PAF:Pan African Resources continues a very slow and steady rise, which is the way I like to see it, and the way I made a lot of money from this company in the past. Up 5% this week they are now up 38% altogether and making £544 potential profit. I think they can double from here based on the new project that has recently come on line.
TAP:Taptica announced a merger and soared, but at the end of the week plummeted again. That averaged out as a 7% rise for the week, but they are still 30% down.
IKA:Ilika won Share of the Week 2 weeks ago, then lost a big chunk last week, but this week got it back by climbing 9%. Still a long, long way to go before making up the 61% deficit and breaking even.
Share of the Week is TRX:Tissue Regenix, which issued a very healthy trading statement early in the week and climbed 11%. This still leaves them 61% down, but I am now getting more hopeful of a rally here.
A desperate plunge over the last 2 weeks looks pretty bad
Trendline looks like it will stay up for a while, but in a couple more months the peak will dominate and we'll be in trouble.
The ISA and share portfolios look like this
Cash was just a correction as I checked my account and it was slightly out. I suspect I missed a monthly ISA fee one month, although that's £3.75. This month's fee was covered by a £20 cash bonus I got for transferring some pension money, which I'm just going to take off the fees rather than treat as actual income.
Once again nearly all the drop in value was down to falling profits as the rest of the portfolio stayed pretty stable. OPTI:Optibiotix does rather control the performance week by week.
Drat! The buffer is gone
It's tricky to see, but the accounts have slipped to a loss. I have so much trouble keeping these ones in the black.
The SIPP looks like this after week 167
Cash would normally drop by about £16 with the monthly fees, but most were covered by the transfer bonus. Half the impact was reduced profits, and half was deepening losses. I'm getting a bit edgy - I feel the need to bank some profit, but can't bring myself to sell anything just yet.
Cripplingly bad news about the pension transfer. Legal & General have refused to do it, stating the minimum amount they are willing to transfer is £2,000. They really are bloody useless! It took them almost 2 weeks to come up with that. This means I have to wait another 2 months before I can do the transfer, so may as well forget all my plans as things will be very different then. I've changed the investments in the pension so the go into a safe bonds fund which should guarantee I get the £2,000 every 4 months for my SIPP. It's very frustrating, but the only way I can get my employer contribution, which is half the monthly injection.
It's not dipped far below the recent dips, so still hopeful the buffer can be maintained.
We're below the trendline which is a worry.
The trading account looks like this
That's a surprise - the trading account out-performing the other accounts. There were a few decent rises this week, and it would have been even better if CAML:Central Asia Metals had held on to the mid-week price, which saw it go into profit of £12. If trade talks with China would stop being so volatile there may be a chance for copper prices to sustain their rise. I'm sure it's got nothing to do with the Americans manipulating the market as they alternate between positive and negative statements week after week. I suspect that would be highly illegal - and I'm sure none of them are making any money off the back of it...
Still creeping upwards.
We'll be above the trendline if this continues.
That's it for another week. There's a big probiotics conference next week where OPTI:Optibiotix are presenting three papers. That's going to result in some pretty massive industry exposure, and hopefully yet more deals. Surely these back-to-back 6% declines have to turn around soon? If they don't then we'll be back in top-up territory. 70p would see me sell a few other shares even at a loss because I really can't see it staying down there for long - if it ever gets there at all.
Worst performer was N4P:N4 Pharma which has seen a mini rally over the last few weeks, but a placing announced today caused the price to plummet down to the placing price, so it's down 15% and losing 56%.
RED:RedT Energy dropped another 8% for no apparent reason, and is sliding relentlessly as holders continue to doubt they can turn a profit, despite having a great product. These are 59% down after looking like things might be improving a few weeks ago.
MMX:Minds + Machines is being played by traders if the recent invasion of the bulletin board by trolls is anything to go on. I still believe this is a very cash generative company - they just need to prove it and dish some out as a dividend. Another 7% drop this week sees it losing 36% now.
IQE:IQE is also under continued shorting pressure, and lacklustre results from the chip manufacturers has hit them badly this week, dropping 6% in my SIPP and 8% in my trading account.
OPTI:Optibiotix dropped 4p (6%) the same as last week, despite more good news. I fear these are set to drift until either news of revenues or one of the anticipated big deals. I still have paper profits of £12,000 which are the only things keeping my portfolios in the black.
There was some good news this week. PAF:Pan African Resources continues a very slow and steady rise, which is the way I like to see it, and the way I made a lot of money from this company in the past. Up 5% this week they are now up 38% altogether and making £544 potential profit. I think they can double from here based on the new project that has recently come on line.
TAP:Taptica announced a merger and soared, but at the end of the week plummeted again. That averaged out as a 7% rise for the week, but they are still 30% down.
IKA:Ilika won Share of the Week 2 weeks ago, then lost a big chunk last week, but this week got it back by climbing 9%. Still a long, long way to go before making up the 61% deficit and breaking even.
Share of the Week is TRX:Tissue Regenix, which issued a very healthy trading statement early in the week and climbed 11%. This still leaves them 61% down, but I am now getting more hopeful of a rally here.
A desperate plunge over the last 2 weeks looks pretty bad
Trendline looks like it will stay up for a while, but in a couple more months the peak will dominate and we'll be in trouble.
The ISA and share portfolios look like this
| Weekly Change | |||
| Cash | £39.24 | -£3.67 | |
| Portfolio cost | £56,971.94 | +£0 | |
| Portfolio sell value (bid price - commission) | £56,841.57 | (-0.2%) | -£1,939.78 |
| Potential profits | £8,720.25 | -£1,920.54 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £136.83 | (2.9%) | -£5.26 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £488.78 | (10.3%) | -£2.68 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash was just a correction as I checked my account and it was slightly out. I suspect I missed a monthly ISA fee one month, although that's £3.75. This month's fee was covered by a £20 cash bonus I got for transferring some pension money, which I'm just going to take off the fees rather than treat as actual income.
Once again nearly all the drop in value was down to falling profits as the rest of the portfolio stayed pretty stable. OPTI:Optibiotix does rather control the performance week by week.
Drat! The buffer is gone
It's tricky to see, but the accounts have slipped to a loss. I have so much trouble keeping these ones in the black.
The SIPP looks like this after week 167
| Weekly Change | |||
| Cash | £122.76 | -£0.08 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £40,814.39 | (7.9%) | -£2,236.29 |
| Potential profits | £6,897.59 | -£1,034.85 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£12.30 | (-0.4%) | +£1.20 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £300.32 | (9.5%) | -£1.81 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash would normally drop by about £16 with the monthly fees, but most were covered by the transfer bonus. Half the impact was reduced profits, and half was deepening losses. I'm getting a bit edgy - I feel the need to bank some profit, but can't bring myself to sell anything just yet.
Cripplingly bad news about the pension transfer. Legal & General have refused to do it, stating the minimum amount they are willing to transfer is £2,000. They really are bloody useless! It took them almost 2 weeks to come up with that. This means I have to wait another 2 months before I can do the transfer, so may as well forget all my plans as things will be very different then. I've changed the investments in the pension so the go into a safe bonds fund which should guarantee I get the £2,000 every 4 months for my SIPP. It's very frustrating, but the only way I can get my employer contribution, which is half the monthly injection.
It's not dipped far below the recent dips, so still hopeful the buffer can be maintained.
We're below the trendline which is a worry.
The trading account looks like this
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,490.65 | (-35.8%) | +£13.68 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £29.05 | (15%) | -£1.03 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.49 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
That's a surprise - the trading account out-performing the other accounts. There were a few decent rises this week, and it would have been even better if CAML:Central Asia Metals had held on to the mid-week price, which saw it go into profit of £12. If trade talks with China would stop being so volatile there may be a chance for copper prices to sustain their rise. I'm sure it's got nothing to do with the Americans manipulating the market as they alternate between positive and negative statements week after week. I suspect that would be highly illegal - and I'm sure none of them are making any money off the back of it...
Still creeping upwards.
We'll be above the trendline if this continues.
That's it for another week. There's a big probiotics conference next week where OPTI:Optibiotix are presenting three papers. That's going to result in some pretty massive industry exposure, and hopefully yet more deals. Surely these back-to-back 6% declines have to turn around soon? If they don't then we'll be back in top-up territory. 70p would see me sell a few other shares even at a loss because I really can't see it staying down there for long - if it ever gets there at all.
Saturday, 2 February 2019
Week 182 Review - Fairly flat apart from a little Optibiotix dip
A relatively flat week for most of the portfolio, but a 4p drop in OPTI:Optibiotix was enough to bring the combined value down by £2,473, reducing the buffer between value and cost to £5,190 and the portfolio value down to £102,493.
Worst performer was last week's Share of the Week IKA:Ilika, which dropped 8% after climbing 20% last week. Not surprising that people would take profits. A long time till I'll be in a position to consider that as these are 50% down.
OPTI:Optibiotix dropped the 4p it climbed last week and so fell 6%. That is worth £3,200 so the fact the combined portfolios only dropped £2,473 suggests there were some big gains elsewhere.
SAE:Simec Atlantis Energy had a mini revival a few weeks ago, but is starting to slip again. It fell 5% this week and is now 72% down. Still no sign of when revenues might come in, so not one I would add to even at these low prices.
MAIS:Maistro climbed 6% this week. I still think it's doomed, but now my average price has reduced massively to 6.34p I may yet salvage something. To think these once traded at 800p. Someone will have lost a hell of a lot on this one!
CAML:Central Asia Metals finally seems to be heading back in the right direction as the China trade talks are getting more optimistic. They went up 8% this week and are now at 28% profit. This is a big holding, so the rise was worth quite a lot.
TLOU:Tlou Energy gave a robust update and climbed 9% so they are only down by 32% now. I've made over £1,500 profit from my previous holdings, so do like this company and am pretty sure they will come good again. However it's high risk and I'm becoming less willing to invest in these types of venture. Granting of the Power Purchase Agreement should see them soar.
TAP:Taptica wins Share of the Week after announcing a merger which will effectively see them take over another company. They climbed by 11% but are still down 37% after the resignation of their CEO. I belive that doesn't impact the company as badly as the share price suggests, so am confident I'll be able to sell these at a profit sometime soon.
Still bouncing every week, but didn't drop as low as 2 weeks ago.
I think I have a few more months where the trend line will point upwards, but the big spike six months ago will start to have an increasing influence so the portfolio needs to get back up there.
The ISA and share accounts look like this
The drop this week is pretty much all down to OPTI:Optibiotix, which isn't a surprise as it's about half my portfolio. None of the other shares stand much chance competing for attention. Losses were reduced by around £80 and performance is clinging above 10%.
Still the right side of the line
These accounts have a long history of being on the red, so this is a great sustained period of profit now. Will it become the norm?
The SIPP looks like this after week 166
Good gains by the likes of CAML:Central Asia Metals and small gains from both PAF:Pan African Resources and CEY:Centamin helped reduce the impact on the profits from the OPTI:Optibiotix drop, but the rest of the portfolio lost an additional £50.
The pension transfer still hasn't shown up, but should arrive next week. Unfortunately CAML:Central Asia Metals may have climbed too much for me to want to put it there. It was a definite buy at 225p but 239p getting a bit much with it being so volatile. I might get back into CWR:Ceres Power as a lack of news has caused them to drift from over 200p to 158p. I still believe there's massive potential in using their technology for distributed power generation, so if the price stays low maybe now is the time to strike.
I'm still gutted that VRS:Versarien won't drop to a price that I'm willing to buy back in. They are so far away from being profitable that I can't justify 130p. It's just like when I got carried away with OPTI:Optibiotix being the next great thing and bought at an inflated price 3 years before they would be profitable, only to see it plummet when this sank in. I'm pretty sure the same will happen to VRS:Versarien, but it hasn't yet. My target to buy back in is when it dips below 100p, but I doubt this will coincide with a pension transfer so I may have to sell something when (or if) the time comes. I do desperately want to be a long term VRS:Versarien shareholder though.
Still looking healthy
A long history of profitability continues.
The trading account looks like this after week 132
The best week for a while, mainly thanks to a big rise in CAML:Central Asia Metals which is now incredibly close to being in profit, and TAP:Taptica which is recovering fast. Target price for selling CAML:Central Asia Metals is 300p and it's at 238p now and was around 348p less than a year ago, so I'm confident the target is in sight. Meanwhile TAP:Taptica needs to get to 300p just to break even, and that's only at 197p so could take a while. Target price to sell IQE:IQE is 130p and that's only 73p at the moment so a long way to go there. The other two (LION:Lionsgold and TEK:Tekcapital) are a waste of space so no point in even mentioning them.
Oooh - there's definitely a change in direction going on.
A long, long way from changing the direction of the trend line, but there's hope.
No news from OPTI:Optibiotix this week, so fingers crossed for next week. The most worrying thing was the remarkably small number of trades in OPTI:Optibiotix shares during the week. It's ripe for manipulation at the moment, so there is a little part of me that is considering sitting on the £1,000 pension transfer in cash for a bit so I can strike should there be a sudden dip in OPTI:Optibiotix or VRS:Versarien - although the CWR:Ceres Power option is going to be difficult to resist.
Worst performer was last week's Share of the Week IKA:Ilika, which dropped 8% after climbing 20% last week. Not surprising that people would take profits. A long time till I'll be in a position to consider that as these are 50% down.
OPTI:Optibiotix dropped the 4p it climbed last week and so fell 6%. That is worth £3,200 so the fact the combined portfolios only dropped £2,473 suggests there were some big gains elsewhere.
SAE:Simec Atlantis Energy had a mini revival a few weeks ago, but is starting to slip again. It fell 5% this week and is now 72% down. Still no sign of when revenues might come in, so not one I would add to even at these low prices.
MAIS:Maistro climbed 6% this week. I still think it's doomed, but now my average price has reduced massively to 6.34p I may yet salvage something. To think these once traded at 800p. Someone will have lost a hell of a lot on this one!
CAML:Central Asia Metals finally seems to be heading back in the right direction as the China trade talks are getting more optimistic. They went up 8% this week and are now at 28% profit. This is a big holding, so the rise was worth quite a lot.
TLOU:Tlou Energy gave a robust update and climbed 9% so they are only down by 32% now. I've made over £1,500 profit from my previous holdings, so do like this company and am pretty sure they will come good again. However it's high risk and I'm becoming less willing to invest in these types of venture. Granting of the Power Purchase Agreement should see them soar.
TAP:Taptica wins Share of the Week after announcing a merger which will effectively see them take over another company. They climbed by 11% but are still down 37% after the resignation of their CEO. I belive that doesn't impact the company as badly as the share price suggests, so am confident I'll be able to sell these at a profit sometime soon.
Still bouncing every week, but didn't drop as low as 2 weeks ago.
I think I have a few more months where the trend line will point upwards, but the big spike six months ago will start to have an increasing influence so the portfolio needs to get back up there.
The ISA and share accounts look like this
| Weekly Change | |||
| Cash | £42.91 | +£0 | |
| Portfolio cost | £56,971.94 | +£0 | |
| Portfolio sell value (bid price - commission) | £58,781.35 | (3.2%) | -£1,811.75 |
| Potential profits | £10,640.79 | -£1,889.55 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £142.09 | (3%) | -£5.68 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £491.46 | (10.4%) | -£2.72 |
| (Sold stocks profit + Dividends - Fees / Months) |
The drop this week is pretty much all down to OPTI:Optibiotix, which isn't a surprise as it's about half my portfolio. None of the other shares stand much chance competing for attention. Losses were reduced by around £80 and performance is clinging above 10%.
Still the right side of the line
These accounts have a long history of being on the red, so this is a great sustained period of profit now. Will it become the norm?
The SIPP looks like this after week 166
| Weekly Change | |||
| Cash | £122.84 | +£0 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £42,050.68 | (11.2%) | -£723.33 |
| Potential profits | £7,932.44 | -£676.83 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£13.50 | (-0.4%) | +£1.50 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £302.13 | (9.6%) | -£1.83 |
| (Sold stocks profit + Dividends - Fees / Months) |
Good gains by the likes of CAML:Central Asia Metals and small gains from both PAF:Pan African Resources and CEY:Centamin helped reduce the impact on the profits from the OPTI:Optibiotix drop, but the rest of the portfolio lost an additional £50.
The pension transfer still hasn't shown up, but should arrive next week. Unfortunately CAML:Central Asia Metals may have climbed too much for me to want to put it there. It was a definite buy at 225p but 239p getting a bit much with it being so volatile. I might get back into CWR:Ceres Power as a lack of news has caused them to drift from over 200p to 158p. I still believe there's massive potential in using their technology for distributed power generation, so if the price stays low maybe now is the time to strike.
I'm still gutted that VRS:Versarien won't drop to a price that I'm willing to buy back in. They are so far away from being profitable that I can't justify 130p. It's just like when I got carried away with OPTI:Optibiotix being the next great thing and bought at an inflated price 3 years before they would be profitable, only to see it plummet when this sank in. I'm pretty sure the same will happen to VRS:Versarien, but it hasn't yet. My target to buy back in is when it dips below 100p, but I doubt this will coincide with a pension transfer so I may have to sell something when (or if) the time comes. I do desperately want to be a long term VRS:Versarien shareholder though.
Still looking healthy
A long history of profitability continues.
The trading account looks like this after week 132
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,476.97 | (-36.4%) | +£61.39 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £30.08 | (15.6%) | -£1.12 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.50 | (-0.8%) | +£0.02 |
| (Sold stocks profit + Dividends - Fees / Months) |
The best week for a while, mainly thanks to a big rise in CAML:Central Asia Metals which is now incredibly close to being in profit, and TAP:Taptica which is recovering fast. Target price for selling CAML:Central Asia Metals is 300p and it's at 238p now and was around 348p less than a year ago, so I'm confident the target is in sight. Meanwhile TAP:Taptica needs to get to 300p just to break even, and that's only at 197p so could take a while. Target price to sell IQE:IQE is 130p and that's only 73p at the moment so a long way to go there. The other two (LION:Lionsgold and TEK:Tekcapital) are a waste of space so no point in even mentioning them.
Oooh - there's definitely a change in direction going on.
A long, long way from changing the direction of the trend line, but there's hope.
No news from OPTI:Optibiotix this week, so fingers crossed for next week. The most worrying thing was the remarkably small number of trades in OPTI:Optibiotix shares during the week. It's ripe for manipulation at the moment, so there is a little part of me that is considering sitting on the £1,000 pension transfer in cash for a bit so I can strike should there be a sudden dip in OPTI:Optibiotix or VRS:Versarien - although the CWR:Ceres Power option is going to be difficult to resist.
Sunday, 27 January 2019
Week 181 Review - Great gains all around
The wider portfolio had a really good week, with encouraging gains in many holdings that have been suffering lately. OPTI:Optibiotix was up 4p too, which contributed £3,200 to the £3,667 rise. This puts the buffer between value and cost at £7,664 and the total portfolio value at £104,967.
Biggest loser was BLU:Blue Star Capital which has been suspended for the last six months as it attempted a reverse takeover of Satoshipay. Unfortunately they couldn't raise enough funds to do the deal so it's been suspended and the shares suffered accordingly, with a 12% fall. These were only a small "toe in the water" purchase, and it's a good job because not only have they failed in this transaction, but Satoshipay are failing to get any major publishers interested in their micro payment system, so this could easily go pop.
CAML:Central Asia Metals tried its best to spoil the party this week, with a 6% fall being quite expensive and preventing paper profits being anywhere near what they could have been. I wish the China standoff would sort itself out so base metal prices can start rising again, but there's no sign of that. I am about to get £1,000 pension transfer though, so will be taking advantage of the low price to top up.
MMX:Minds + Machines dropped 6% and keep slipping, and I guess will continue until they release some financial results from the new enlarged company. I'm reasonably confident that these results will be good and the price will soar, but not confident enough to invest any more money in them.
Those were the big losers. There were far more big risers.
OPTI:Optibiotix recovered the 4p they lost last week to climb 6% and go back to 90p. News has to be close now, and I have a feeling the next one could be mega, as there are so many coals in the fire. Could it be the retail contract? Could it be a Sweetbiotix deal? Could it be the Tata announcement? Will there be a trading statement? So much excitement!
IQE:IQE are marching upwards, and climbed another 7% this week. It's possible the shorters are gradually closing their positions. If I was feeling brave I'd buy some, but I think CAML:Central Asia Metals is a better bet at the moment.
TAP:Taptica are slowly recovering from their recent unjustified hammering. This week they are up 7% but are still 47% down overall.
N4P:N4 Pharma are also attracting more interest now their Nuvec product is being developed. An 8% climb this week leaves them only 44% down, which is 20% better than after the initial crash when the Viagra replacement didn't work.
PAF:Pan African Resources issued a superb trading statement and I was surprised they only climbed 11%. This has been a good slow steady climb though, leaving them 31% up and with paper profit of £450.
SBTX:SkinBioTherapeutics have also been improving gradually. My ISA holding climbed by 12% and my SIPP by 14% leaving my ISA down by 19% and my SIPP up by 23%. My target for selling the SIPP holding is 20p, after which I'll sell and hope for a dip. Meanwhile I'll keep the ISA holding until 25p and do the same. The ultimate aim is to increase the number of shares I hold until I get to the stage where I just keep them.
Share of the Week is IKA:Ilika which I think benefited from an article in II which recommended them, along with MTFB:Motif Bio and OPTI:Optibiotix. The other two didn't respond as dramatically as IKA:Ilika, which climbed 20%. Not great news though, as my holding is still down by 42% and needs a lot more good news before I can ditch them.
Back to where we were two weeks ago.
The portfolio seems to have hit a point of resistance at around £7,000 in profit.
Here's the ISA and share portfolios performance
The increase in profit is all from OPTI:Optibiotix, with MTFB:Motif Bio robbing a bit of that, and around £180 reduction in losses from the other shares. Slow and steady!
Bouncing along just the right side of the line.
Still an upward trend but still only just the right side of £0. Much better picture than the first half of 2018 though.
The SIPP looks like this after week 165
Similar story to the other account, although a much wider contribution to increased profits, and a bigger dent in them from the drop in CAML:Central Asia Metals. Losses were reduced by around £230 which is good news. LLOY:Lloyds is only 4% under now, and if that can get into profit then 6 out of the 11 shares will be in profit, and it's been a while since I could say more than half in the portfolio was in the black. Compare that to the ISA and share accounts where only 2 out of 17 are in profit.
Hopefully I'll be adding another £1,000 next week, but that will increase the cost and lower the average performance rating, already below 10% since the big injection before Christmas. The desire to sell something and get back above 10% is growing, and I'm still targeting SBTX:SkinBioTherapeutics to do that. Potential profit is currently £225 which would lift me from 9.6% to 9.8% so it's not enough. 20p would get £487 profit, which would take me to exactly 10%. It would only stay above target for a week though.
Looking mighty fine.
The buffer is £5,000 which is encouraging. The worry is that this will drop if I sell something.
Here's the trading account after week 131
A good increase of £40, but last week's drop was £45 so this is still going backwards. Most frustrating that the big loser this week was CAML:Central Asia Metals, which is the one that looked closest to going into profit. It's now 11% down and looking far away from providing any income. It's a good job the £2,000 I borrowed to start this was interest free, as I'm not making any sort of return on it.
Actually, I think the last 6 weeks have seen a slight increase - could there be hope?
Maybe just a fools hope...
I haven't a clue what's likely to happen next week. If the £1,000 turns up then at the moment it's going on CAML:Central Asia Metals, especially if it drops lower. If it spikes upwards I'll have to re-think. Contenders are CEY:Centamin as it's still under-valued, IQE:IQE as I would have considered 75p ludicrously cheap 6 months ago, PRU:Prudential because I've wanted to start building a position there for years and I saw loads of evidence of their presence on a recent trip to Vietnam, or LLOY:Lloyds as they are slowly sneaking up and PPI is a thing of the past suggesting a return to healthy dividends - but what of the Brexit bogey?
Biggest loser was BLU:Blue Star Capital which has been suspended for the last six months as it attempted a reverse takeover of Satoshipay. Unfortunately they couldn't raise enough funds to do the deal so it's been suspended and the shares suffered accordingly, with a 12% fall. These were only a small "toe in the water" purchase, and it's a good job because not only have they failed in this transaction, but Satoshipay are failing to get any major publishers interested in their micro payment system, so this could easily go pop.
CAML:Central Asia Metals tried its best to spoil the party this week, with a 6% fall being quite expensive and preventing paper profits being anywhere near what they could have been. I wish the China standoff would sort itself out so base metal prices can start rising again, but there's no sign of that. I am about to get £1,000 pension transfer though, so will be taking advantage of the low price to top up.
MMX:Minds + Machines dropped 6% and keep slipping, and I guess will continue until they release some financial results from the new enlarged company. I'm reasonably confident that these results will be good and the price will soar, but not confident enough to invest any more money in them.
Those were the big losers. There were far more big risers.
OPTI:Optibiotix recovered the 4p they lost last week to climb 6% and go back to 90p. News has to be close now, and I have a feeling the next one could be mega, as there are so many coals in the fire. Could it be the retail contract? Could it be a Sweetbiotix deal? Could it be the Tata announcement? Will there be a trading statement? So much excitement!
IQE:IQE are marching upwards, and climbed another 7% this week. It's possible the shorters are gradually closing their positions. If I was feeling brave I'd buy some, but I think CAML:Central Asia Metals is a better bet at the moment.
TAP:Taptica are slowly recovering from their recent unjustified hammering. This week they are up 7% but are still 47% down overall.
N4P:N4 Pharma are also attracting more interest now their Nuvec product is being developed. An 8% climb this week leaves them only 44% down, which is 20% better than after the initial crash when the Viagra replacement didn't work.
PAF:Pan African Resources issued a superb trading statement and I was surprised they only climbed 11%. This has been a good slow steady climb though, leaving them 31% up and with paper profit of £450.
SBTX:SkinBioTherapeutics have also been improving gradually. My ISA holding climbed by 12% and my SIPP by 14% leaving my ISA down by 19% and my SIPP up by 23%. My target for selling the SIPP holding is 20p, after which I'll sell and hope for a dip. Meanwhile I'll keep the ISA holding until 25p and do the same. The ultimate aim is to increase the number of shares I hold until I get to the stage where I just keep them.
Share of the Week is IKA:Ilika which I think benefited from an article in II which recommended them, along with MTFB:Motif Bio and OPTI:Optibiotix. The other two didn't respond as dramatically as IKA:Ilika, which climbed 20%. Not great news though, as my holding is still down by 42% and needs a lot more good news before I can ditch them.
Back to where we were two weeks ago.
The portfolio seems to have hit a point of resistance at around £7,000 in profit.
Here's the ISA and share portfolios performance
| Weekly Change | |||
| Cash | £42.91 | +£0 | |
| Portfolio cost | £56,971.94 | +£0 | |
| Portfolio sell value (bid price - commission) | £60,593.10 | (6.4%) | +£2,174.89 |
| Potential profits | £12,530.34 | +£1,992.85 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £147.77 | (3.1%) | -£6.16 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £494.18 | (10.4%) | -£2.74 |
| (Sold stocks profit + Dividends - Fees / Months) |
The increase in profit is all from OPTI:Optibiotix, with MTFB:Motif Bio robbing a bit of that, and around £180 reduction in losses from the other shares. Slow and steady!
Bouncing along just the right side of the line.
Still an upward trend but still only just the right side of £0. Much better picture than the first half of 2018 though.
The SIPP looks like this after week 165
| Weekly Change | |||
| Cash | £122.84 | +£0 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £42,774.01 | (13.1%) | +£1,451.82 |
| Potential profits | £8,609.27 | +£1,220.99 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£15.00 | (-0.5%) | +£1.88 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £303.96 | (9.6%) | -£1.86 |
| (Sold stocks profit + Dividends - Fees / Months) |
Similar story to the other account, although a much wider contribution to increased profits, and a bigger dent in them from the drop in CAML:Central Asia Metals. Losses were reduced by around £230 which is good news. LLOY:Lloyds is only 4% under now, and if that can get into profit then 6 out of the 11 shares will be in profit, and it's been a while since I could say more than half in the portfolio was in the black. Compare that to the ISA and share accounts where only 2 out of 17 are in profit.
Hopefully I'll be adding another £1,000 next week, but that will increase the cost and lower the average performance rating, already below 10% since the big injection before Christmas. The desire to sell something and get back above 10% is growing, and I'm still targeting SBTX:SkinBioTherapeutics to do that. Potential profit is currently £225 which would lift me from 9.6% to 9.8% so it's not enough. 20p would get £487 profit, which would take me to exactly 10%. It would only stay above target for a week though.
Looking mighty fine.
The buffer is £5,000 which is encouraging. The worry is that this will drop if I sell something.
Here's the trading account after week 131
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,415.58 | (-39%) | +£40.92 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £31.20 | (16.1%) | -£1.20 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.52 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
A good increase of £40, but last week's drop was £45 so this is still going backwards. Most frustrating that the big loser this week was CAML:Central Asia Metals, which is the one that looked closest to going into profit. It's now 11% down and looking far away from providing any income. It's a good job the £2,000 I borrowed to start this was interest free, as I'm not making any sort of return on it.
Actually, I think the last 6 weeks have seen a slight increase - could there be hope?
Maybe just a fools hope...
I haven't a clue what's likely to happen next week. If the £1,000 turns up then at the moment it's going on CAML:Central Asia Metals, especially if it drops lower. If it spikes upwards I'll have to re-think. Contenders are CEY:Centamin as it's still under-valued, IQE:IQE as I would have considered 75p ludicrously cheap 6 months ago, PRU:Prudential because I've wanted to start building a position there for years and I saw loads of evidence of their presence on a recent trip to Vietnam, or LLOY:Lloyds as they are slowly sneaking up and PPI is a thing of the past suggesting a return to healthy dividends - but what of the Brexit bogey?
Saturday, 19 January 2019
Week 180 Review - The 2019 good times grind to a halt
The positive start to 2019 lasted just 2 weeks. Bugger! The combined portfolios dropped by £3,213 and pretty much all of that was down to a 4p drop in OPTI:Optibiotix. The buffer between value and cost was reduced to £3,996 and total value down to £101,299.
Worst performer was TAP:Taptica dropping 13%, making me really glad I didn't invest any more thinking it had reached a bottom. The suspension of the share buy back scheme is a real worry, although in theory the reasons are good as they claim to have a potential acquisition. However why announce the buy-back in the first place? I'm glad it's just my cursed trading account and really annoyed I didn't take £100 profit when I had the chance.
OPTI:Optibiotix dropped 4p which is 6% and £3,200. There was no news this week, but that usually sees an increase. Some new trolls have appeared on the bulletin board so it's possible traders are targeting it to try and get the price down. Presumably they took their profits at 90p and want back in!
CEY:Centamin dropped 5% this week which is a surprise given that the price of gold is doing much better.
IKA:Ilika gave quite an upbeat statement today which fired a glimmer of hope they may be able to commercialise something after all. The share price is up 5% on the week, but still 62% down from when I bought them.
LLOY:Lloyds Bank are creeping back towards profit, climbing 5% this week and are only 5% down overall. I'll be getting another £1,000 from my SIPP in a few weeks so may put it here.
N4P:N4 Pharma wins Share of the Week with a 7% climb. No particular reason I can see, and a long long way before I recover my 52% loss.
All last week's gains have gone. Note I've removed the trend line as it doesn't really give a true reflection when the increase in cost isn't taken into account. That's now covered by the chart below.
So frustrating that there was such a big spike 5 months ago and it lasted such a short time. Now only just in the black but the trend line is still pointing up, and that's based on the difference between cost and value so doesn't artificially increase as the costs go up from buying more.
Here's the performance of the ISA and share accounts
All losses down to reduced profit, and most of that was OPTI:Optibiotix with a small positive contribution from MTFB:Motif Bio which climbed 1%.
Still in the black but only just.
The trend line is still improving, but when the earlier lows get nudged off the left hand side of the chart, we're in for a severe reversal if the current buffer can't get back to £20K.
Here's the SIPP after week 164
Similar story to the other account, but this time the rest of the portfolio fought back and managed to improve the losses by about £180. I really need to clock up some realised profit so the average can get back above 10%. For that I need some good news from SBTX:SkinBioTherapeutics as that's the best candidate for a sale. The current £37 paper profit isn't going to help my stats much though.
Looking much better than the other accounts
Still have the big spike in the middle which could disrupt the trend line later.
Here's the trading account after week 130
IQE:IQE helped limit the losses from other dips, as this account continues to disappoint horribly.
Still no prospect of moving the orange line down to £0.
Desperate.
That's it for this week - and finished just in time for the footie!
Worst performer was TAP:Taptica dropping 13%, making me really glad I didn't invest any more thinking it had reached a bottom. The suspension of the share buy back scheme is a real worry, although in theory the reasons are good as they claim to have a potential acquisition. However why announce the buy-back in the first place? I'm glad it's just my cursed trading account and really annoyed I didn't take £100 profit when I had the chance.
OPTI:Optibiotix dropped 4p which is 6% and £3,200. There was no news this week, but that usually sees an increase. Some new trolls have appeared on the bulletin board so it's possible traders are targeting it to try and get the price down. Presumably they took their profits at 90p and want back in!
CEY:Centamin dropped 5% this week which is a surprise given that the price of gold is doing much better.
IKA:Ilika gave quite an upbeat statement today which fired a glimmer of hope they may be able to commercialise something after all. The share price is up 5% on the week, but still 62% down from when I bought them.
LLOY:Lloyds Bank are creeping back towards profit, climbing 5% this week and are only 5% down overall. I'll be getting another £1,000 from my SIPP in a few weeks so may put it here.
N4P:N4 Pharma wins Share of the Week with a 7% climb. No particular reason I can see, and a long long way before I recover my 52% loss.
All last week's gains have gone. Note I've removed the trend line as it doesn't really give a true reflection when the increase in cost isn't taken into account. That's now covered by the chart below.
So frustrating that there was such a big spike 5 months ago and it lasted such a short time. Now only just in the black but the trend line is still pointing up, and that's based on the difference between cost and value so doesn't artificially increase as the costs go up from buying more.
Here's the performance of the ISA and share accounts
| Weekly Change | |||
| Cash | £42.91 | +£0 | |
| Portfolio cost | £56,971.94 | +£0 | |
| Portfolio sell value (bid price - commission) | £58,418.21 | (2.5%) | -£2,003.29 |
| Potential profits | £10,537.49 | -£2,013.51 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £153.93 | (3.2%) | -£6.69 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £496.92 | (10.5%) | -£2.78 |
| (Sold stocks profit + Dividends - Fees / Months) |
All losses down to reduced profit, and most of that was OPTI:Optibiotix with a small positive contribution from MTFB:Motif Bio which climbed 1%.
Still in the black but only just.
The trend line is still improving, but when the earlier lows get nudged off the left hand side of the chart, we're in for a severe reversal if the current buffer can't get back to £20K.
Here's the SIPP after week 164
| Weekly Change | |||
| Cash | £122.84 | +£0 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,322.19 | (9.2%) | -£1,166.94 |
| Potential profits | £7,388.28 | -£1,342.13 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£16.88 | (-0.5%) | +£2.41 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0.03 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £305.82 | (9.7%) | -£1.87 |
| (Sold stocks profit + Dividends - Fees / Months) |
Similar story to the other account, but this time the rest of the portfolio fought back and managed to improve the losses by about £180. I really need to clock up some realised profit so the average can get back above 10%. For that I need some good news from SBTX:SkinBioTherapeutics as that's the best candidate for a sale. The current £37 paper profit isn't going to help my stats much though.
Looking much better than the other accounts
Still have the big spike in the middle which could disrupt the trend line later.
Here's the trading account after week 130
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,374.66 | (-40.8%) | -£43.75 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £32.40 | (16.7%) | -£1.29 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.53 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
IQE:IQE helped limit the losses from other dips, as this account continues to disappoint horribly.
Still no prospect of moving the orange line down to £0.
Desperate.
That's it for this week - and finished just in time for the footie!
Subscribe to:
Posts (Atom)